Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

Annals of Oncology

Volumn 11, Issue 8, 2000, Pages 1029-1033

  Safra, T ^a   Muggia, F ^b   Jeffers, S ^a   Tsao Wei, D D ^a   Groshen, S ^a   Lyass, O ^c   Henderson, R ^a   Berry, G ^d   Gabizon, A ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac toxicity; Endomyocardial biopsy scores; Liposomal doxorubicin; MUGA scans

Indexed keywords

DOXORUBICIN; LIPOSOME; STEALTH LIPOSOMAL DOXORUBICIN HCL;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG FORMULATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; DOXORUBICIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0033802643     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008365716693     Document Type: Article

References (26)

1. Risk factors for doxorubicin-induced congestive heart failure
2. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule
3. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
4. Strategies for reduction of anthracycline cardiac toxicity
5. Anthracycline analogues and carriers
6. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs
7. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
8. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes
9. Phase II trial of liposome-encapsulated doxorubcin, cyclophosphamide and fluorouracil as first-line therapy in patients with metastatic breast cancer
10. Liposomal anthracyclines
11. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
12. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
13. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma
14. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin
15. Liposomes as in vivo carriers of adriamycin: Reduced cardiac uptake and preserved antitumor activity
16. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice
17. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times
18. Sterically stabilized liposomes: Improvements in pharmacokinetics and anti-tumor therapeutic efficacy
19. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors
20. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
21. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
22. Doxil in breast cancer
23. Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose- and sequence-finding study
24. Cardiotoxicity if epirubicin-paclitaxel-containing regimens: Role of cardiac risk factors
25. Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation
26. Characterization of cardiac dysfunction observed in Herceptin (trastuzumab) clinical trials